G01N33/78

THYROGLOBULIN QUANTITATION BY MASS SPECTROMETRY
20230236200 · 2023-07-27 ·

Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.

THYROGLOBULIN QUANTITATION BY MASS SPECTROMETRY
20230236200 · 2023-07-27 ·

Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.

TREATMENT OF PSYCHIATRIC CONDITIONS SUCH AS RESISTANT DEPRESSION, BIPOLAR DISORDER AND/OR MAJOR DEPRESSIVE DISORDER VIA APPLICATION OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION WITH THYROID HORMONE TREATMENT AND/OR QUETIAPINE
20230218916 · 2023-07-13 · ·

The present invention relates to treatment of a psychiatric condition, for example resistant depression (RD), bipolar disorder (either threshold or sub-threshold) and/or major depressive disorder via application of repetitive transcranial magnetic stimulation with a drug treatment, in particular application of repetitive transcranial magnetic stimulation with treatment to modulate the activity of the neurones and induce neuroplasticity and the use of Thyroid hormone treatment to increase quantity or activity of thyroid hormones, for example for treatment of thyroid dysfunction. Patients may be selected for treatment by testing for the presence of normal thyroid function.

Thyroglobulin quantitation by mass spectrometry

Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.

Thyroglobulin quantitation by mass spectrometry

Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.

REAL-TIME G-PROTEIN COUPLED RECEPTOR (GPCR) LINKED BIOLUMINESCENT SENSING OF BIOLOGICAL TARGETS AND PROCESSES

The invention relates to compositions and methods for making and use of a real-time cellular sensor. Components of a multipart enzyme are sequestered in different cellular compartments and only come together after receptor activation; a pool of substrate is made available in the cell to ensure real-time enzymatic output.

Device for quantitative measurement of thyroid hormones

The present application relates to a method for detecting and monitoring the level of thyroid hormones in an individual and a device for carrying out the same.

Device for quantitative measurement of thyroid hormones

The present application relates to a method for detecting and monitoring the level of thyroid hormones in an individual and a device for carrying out the same.

COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION
20230147865 · 2023-05-11 ·

A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION
20230147865 · 2023-05-11 ·

A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.